Penumbra, Inc. (PEN)
322.17
+1.03
(+0.32%)
USD |
NYSE |
Sep 04, 16:00
322.19
+0.02
(+0.01%)
After-Hours: 20:00
Penumbra Research and Development Expense (Quarterly) : 19.96M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 19.96M |
| March 31, 2026 | 17.99M |
| December 31, 2025 | 17.52M |
| September 30, 2025 | 20.37M |
| June 30, 2025 | 23.22M |
| March 31, 2025 | 22.08M |
| December 31, 2024 | 20.01M |
| September 30, 2024 | 25.20M |
| June 30, 2024 | 24.94M |
| March 31, 2024 | 24.63M |
| December 31, 2023 | 21.94M |
| September 30, 2023 | 20.96M |
| June 30, 2023 | 21.54M |
| March 31, 2023 | 19.99M |
| December 31, 2022 | 17.96M |
| September 30, 2022 | 21.32M |
| June 30, 2022 | 19.56M |
| March 31, 2022 | 20.56M |
| December 31, 2021 | 52.00M |
| September 30, 2021 | 16.73M |
| June 30, 2021 | 17.74M |
| March 31, 2021 | 18.08M |
| December 31, 2020 | 19.46M |
| September 30, 2020 | 34.92M |
| Date | Value |
|---|---|
| June 30, 2020 | 20.22M |
| March 31, 2020 | 12.95M |
| December 31, 2019 | 12.86M |
| September 30, 2019 | 13.73M |
| June 30, 2019 | 13.46M |
| March 31, 2019 | 11.67M |
| December 31, 2018 | 10.87M |
| September 30, 2018 | 9.092M |
| June 30, 2018 | 8.193M |
| March 31, 2018 | 8.013M |
| December 31, 2017 | 8.401M |
| September 30, 2017 | 8.132M |
| June 30, 2017 | 8.094M |
| March 31, 2017 | 7.034M |
| December 31, 2016 | 6.113M |
| September 30, 2016 | 6.497M |
| June 30, 2016 | 6.264M |
| March 31, 2016 | 5.001M |
| December 31, 2015 | 5.484M |
| September 30, 2015 | 4.56M |
| June 30, 2015 | 4.792M |
| March 31, 2015 | 3.191M |
| June 30, 2014 | 4.077M |
| March 31, 2014 | 3.461M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Boston Scientific Corp. | 554.00M |
| Globus Medical, Inc. | 36.32M |
| Teleflex, Inc. | 45.12M |
| Abbott Laboratories | 892.00M |
| AngioDynamics, Inc. | 8.178M |